Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Response Biomedical closes US$12.6 million unit offering

Fasken
Reading Time 1 minute read Subscribe
Client

Haywood Securities Inc.

On May 21, 2009, Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF), a Canadian company that develops, manufactures and markets rapid on-site diagnostic tests, announced that it had closed its previously announced public offering of units for gross proceeds of $12.65 million. Response issued 73,333,333 Units at a price of $0.15 per Unit. The company concurrently issued an additional 11,000,000 Units pursuant to the exercise-in-full of an over-allotment option granted to Haywood Securities Inc., sole underwriter of the offering. Net proceeds of the offering will be used primarily for general operating expenses and a small percentage for capital acquisitions related to manufacturing capacity expansion to meet product demand created by Response's corporate partnerships with Roche Diagnostics, 3M Health Care and Shionogi & Co., Ltd.Haywood Securities was advised in this transaction by a team from Fasken Martineau led by Blair Horn and that included Steve Saville and Caroline Clapham, with the assistance of paralegal Sara Knappe.

    Subscribe

    Receive email updates from our team

    Subscribe